tramadol + dexmedetomidine

Tramadol + dexmedetomidine is a combination of two pharmaceutical agents used primarily for enhanced analgesia and sedation in perioperative and postoperative settings. Tramadol is a centrally acting synthetic opioid analgesic that acts as an agonist at the μ-opioid receptor, inhibits serotonin reuptake, and inhibits norepinephrine reuptake. Dexmedetomidine is a highly selective α2-adrenoceptor agonist with sedative, anxiolytic, sympatholytic, and modest analgesic properties. The combination has been shown to provide superior pain control compared to tramadol alone in patient-controlled intravenous analgesia (PCIA), with reduced requirements for additional opioids and improved safety profiles regarding common opioid-related side effects such as nausea and vomiting. This combination has also demonstrated benefits in animal anesthesia protocols by reducing anesthetic requirements while maintaining stable cardiorespiratory parameters[1][2][9][10].

Other names

tramadol + dexmedetomidineDEX-tramadolDXM-TMD